Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
as15 (1 trial)
recmage-a3 (1 trial)
Urinary Bladder Neoplasms (Phase 2)
Trials (1 total)
Trial APIs (2 total)